Allison Krug

MPH

Allison Krug is an epidemiologist and program manager with experience leading population health programs. She's the lead author of the first stratified risk-benefit analysis of mRNA vaccination among adolescents and editor for 400+ research manuscripts published in high impact factor, peer-reviewed journals. She's also the founder and CEO of Artemis Biomedical Communications, LLC.

Promise or Peril: COVID-19 mRNA Vaccine Issues Series

December 13, 2023 Original Series
Are Pandemic-Related Excess Deaths Due to COVID or Vaccines? Depends on Who’s Counting (Part 2)

March 27, 2023 Health Viewpoints
Are Australian Excess Deaths Caused by the COVID-19 Vaccine? (Part 1)

March 13, 2023 Health Viewpoints
Hazardous Ingredients of HPV Vaccines Increase Risk to Young People (Part 4)

March 2, 2023 Vaccines
Can HPV Vaccine Prevent Cervical Cancer: Current Studies (Part 3)

January 21, 2023 Health Viewpoints
Concerns of Increased Neurological and Autoimmune Events After HPV Vaccines: Large Studies (Part 2)

January 16, 2023 Vaccines
Evidence of Serious Adverse Events in What Is Believed to Be One of the Most Effective Vaccines (Part 1)

January 15, 2023 Health Viewpoints

Allison Krug

Promise or Peril: COVID-19 mRNA Vaccine Issues Series

Are Pandemic-Related Excess Deaths Due to COVID or Vaccines? Depends on Who’s Counting (Part 2)

Are Australian Excess Deaths Caused by the COVID-19 Vaccine? (Part 1)

Hazardous Ingredients of HPV Vaccines Increase Risk to Young People (Part 4)

Can HPV Vaccine Prevent Cervical Cancer: Current Studies (Part 3)

Concerns of Increased Neurological and Autoimmune Events After HPV Vaccines: Large Studies (Part 2)

Evidence of Serious Adverse Events in What Is Believed to Be One of the Most Effective Vaccines (Part 1)